Send to

Choose Destination
Cold Spring Harb Perspect Med. 2019 Mar 1;9(3). pii: a034942. doi: 10.1101/cshperspect.a034942.

The Genomics of Prostate Cancer: A Historic Perspective.

Author information

Englander Institute for Precision Medicine, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York 10065.
Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, New York 10021.
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10021.
Department of BioMedical Research, University of Bern, 3012 Bern, Switzerland.
Centre for Integrative Biology, University of Trento, 38123 Trento, Italy.


The genomics of prostate cancer (PCA) has been difficult to study compared with some other cancer types for a multitude of reasons, despite significant efforts since the early 1980s. Overcoming some of these obstacles has paved the way for greater insight into the genomics of PCA. The advent of high-throughput technologies coming from the initial use of microsatellite and oligonucleotide probes gave rise to techniques like comparative genomic hybridization (CGH). With the introduction of massively parallel genomic sequencing, referred to as next-generation sequencing (NGS), a deeper understanding of cancer genomics in general has occurred. Along with these technologic advances, there has been the development of computational biology and statistical approaches to address novel large data sets characterized by single base resolution. This review will provide a historic perspective of PCA genomics with an emphasis on the cardinal mutations and alterations observed to be consistently seen in PCA for both hormone-naïve localized PCA and castration-resistant prostate cancer (CRPC). There will be a focus on alterations that have the greatest potential to play a role in disease progression and therapy management.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center